The objective of this study was to investigate possible associations between serum triglyceride and canine pancreatic lipase immunoreactivity (cPLI) concentrations in miniature schnauzers. One hundred and ninety-five miniature schnauzers were enrolled and divided into two groups based on whether they had normal (group 1) or increased (group 2) serum triglyceride concentrations. Serum cPLI concentrations were measured and compared between groups. A significant positive correlation was seen between serum triglyceride and cPLI concentrations (Spearman r=0.321; P<0.0001). Miniature schnauzers with hypertriglyceridemia had a significantly higher median serum cPLI concentration (99.5 microg/L) than miniature schnauzers with normal serum triglyceride concentrations (median cPLI concentration 39.3 microg/L; P=0.0001). A cutoff value of 862 mg/dL was selected for serum triglyceride concentrations based on receiver operator characteristic analysis. Miniature schnauzers with severe hypertriglyceridemia (> or =862 mg/dL) were 4.5 times more likely to have a serum cPLI concentration consistent with pancreatitis (> or =200 microg/L) than miniature schnauzers with a normal serum triglyceride concentration. The present study supports an association between hypertriglyceridemia (especially when severe [> or =862 mg/dL]) and high cPLI concentrations in miniature schnauzers.
"In one study, hypertriacylglycerolemia was present in 32.8% of 192 Miniature Schnauzers investigated . In this breed, hyperlipidemia, and more specifically hypertriacylgly-cerolemia, might be associated with diseases such as hepatobiliary disease, pancreatitis, insulin resistance, and ocular disease [16,17,20,22]. The biochemical, metabolic, and genetic bases of hypertriacylglycerolemia in Miniature Schnauzers have not been identified yet. "
[Show abstract][Hide abstract] ABSTRACT: Background
Despite the importance of abnormalities in lipoprotein metabolism in clinical canine medicine, the fact that most previously used methods for lipoprotein profiling are rather laborious and time-consuming has been a major obstacle to the wide clinical application and use of lipoprotein profiling in this species. The aim of the present study was to assess the feasibility of a continuous lipoprotein density profile (CLPDP) generated within a bismuth sodium ethylenediaminetetraacetic acid (NaBiEDTA) density gradient to characterize and compare the lipoprotein profiles of healthy dogs of various breeds, healthy Miniature Schnauzers, and Miniature Schnauzers with primary hypertriacylglycerolemia. A total of 35 healthy dogs of various breeds with serum triacylglycerol (TAG) and cholesterol concentrations within their respective reference intervals were selected for use as a reference population. Thirty-one Miniature Schnauzers with serum TAG and cholesterol concentrations within their respective reference intervals and 31 Miniature Schnauzers with hypertriacylglyceridemia were also included in the study.
The results suggest that CLPDP using NaBiEDTA provides unique diagnostic information in addition to measurements of serum TAG and cholesterol concentrations and that it is a useful screening method for dogs with suspected lipoprotein metabolism disorders. Using the detailed and continuous density distribution information provided by the CLPDP, important differences in lipoprotein profiles can be detected even among dogs that have serum TAG and cholesterol concentrations within the reference interval. Miniature Schnauzers with serum TAG and cholesterol concentrations within the reference interval had significantly different lipoprotein profiles than dogs of various other breeds. In addition, it was further established that specific lipoprotein fractions are associated with hypertriacylglyceridemia in Miniature Schnauzers.
The results of the present study suggest that density gradient ultracentrifugation using NaBiEDTA is a useful screening method for the study of lipoprotein profiles in dogs. Therefore, this method could potentially be used for diagnostic purposes for the separation of dogs suspected of having lipoprotein abnormalities from healthy dogs.
BMC Veterinary Research 03/2013; 9(1):47. DOI:10.1186/1746-6148-9-47 · 1.78 Impact Factor
" b ; Whitney et al . , 1987 ; Cook et al . , 1993 ; Hess et al . , 1998 , 1999 ; Williams and Steiner , 2005 ) . In a preliminary study , hypertriglyceridemia exceeding 10 . 17 mmol / L ( 900 mg / dL ) was found to be associated with an increased risk for pancreatitis in Miniature Schnauzers , and that might also be true for dogs of other breeds ( Xenoulis et al . , 2006 ) . Secondary hyperlipidemia seen in dogs with some endocrinopathies ( e . g . , hyperadrenocorticism ) or obesity may be responsible for the increased risk for pancreatitis associated with these diseases ( Chikamune et al . , 1995 ; Hess et al . , 1999 , 2000 ) . Based on these studies , an association between hypertriglyceridemia and "
[Show abstract][Hide abstract] ABSTRACT: Lipid metabolism in dogs can be divided into exogenous and endogenous pathways and exhibits some unique characteristics compared to other species. Hyperlipidemia is common in dogs, and can be either primary or secondary to other diseases. Secondary hyperlipidemia is the most common form and can be a result of endocrine disorders, pancreatitis, cholestasis, protein-losing nephropathy, obesity, and high fat diets. Primary hyperlipidemia is less common and usually associated with certain breeds. Hypertriglyceridemia of Miniature Schnauzers is the most common type of primary hyperlipidemia in dogs in the United States, and appears to have a genetic basis although its etiology remains unknown. Possible complications of canine hyperlipidemia include pancreatitis, liver disease, atherosclerosis, ocular disease, and seizures. Management is achieved by administration of low fat diets with or without the administration of lipid-lowering agents such as omega-3 fatty acids, gemfibrozil, and niacin.
The Veterinary Journal 02/2009; 183(1):12-21. DOI:10.1016/j.tvjl.2008.10.011 · 1.76 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: To develop a standardized meal challenge test by assessing associations between food-withheld preprandial (ie, fasting) and postprandial triglyceride concentrations, determining the most appropriate sampling time to detect the peak concentration (highest postprandial concentration), and estimating reference intervals for fasting and postprandial concentrations in healthy dogs.
12 lean healthy mixed-breed dogs.
Dogs were fed a dry commercially available diet (fat, 31% metabolizable energy) for 3 weeks. After food was withheld for 23 to 24 hours, plasma triglyceride concentrations were measured 1 and 0.083 hours before and 1, 2, 3, 4, 5, 6, 9, and 12 hours after feeding of a standardized challenge meal (median amount eaten, 63 kcal/kg [127 kcal/kg⁰.⁷⁵]). Correlation and agreement between concentrations at peak and other time points were assessed by use of correlation coefficients and Bland-Altman limits of agreement. Reference intervals were calculated by use of a robust method.
Fasting and peak triglyceride concentrations were not closely associated. The highest concentration among samples obtained 2, 5, and 6 hours after meal consumption had closest agreement with peak concentration. In 5 of 12 dogs, concentrations 12 hours after eating were still significantly above baseline concentration (mean of each dog's fasting concentrations). Conclusions and
Fasting triglyceride concentration could not be used to accurately predict peak concentration. When estimating peak concentration, multiple samples should be collected 2, 5, and 6 hours after consumption of a standardized meal. Food may need to be withheld for > 12 hours when assessing fasting concentrations in healthy dogs.
American Journal of Veterinary Research 02/2011; 72(2):161-8. DOI:10.2460/ajvr.72.2.161 · 1.34 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.